KRAS and pancreatic neoplasm: The preliminary results of a phase 1 trial evaluating a first-in-class, KRAS-G12D-selective protein degrader, ASP3082, in advanced pancreatic cancer, CRC, and NSCLC showed an acceptable safety profile and promising antitumor activity, especially in pretreated pancreatic cancer [90].